Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Political uncertainty, especially with Trump’s election, has also made investors nervous. In 2024, Novo Nordisk A/S (NYSE:NVO) raised its total dividend per share by 21.3% to DKK 11.40 ...

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 18 unusual trades. Delving into the details, we found 33 ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

It has been about 100 years since Novo Nordisk marketed the first effective drug for diabetes, and although tremendous progress has been made, the Danish company is never fully satisfied.

Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...

Novo Nordisk reported $40.5 billion in sales for 2024, surpassing Wall Street’s expectations. Its success was driven by its two GLP-1 drugs, Ozempic and Wegovy. The company is in a race with ...

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive said, as tensions simmer between Copenhagen and Washington. Trump has ...